Moderna, Goldman Sachs

Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna stock drops as Goldman Sachs cuts rating
Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy.
Moderna down as Goldman Sachs downgrades on revenue outlook
Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Goldman's downgrade comes days after the Cambridge,
Why MRNA Stock Is Retreating
RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
Why Moderna Stock Jumped Over 20% This Week
As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.
bovnews6d
MRNA Unveiled: The Shocking Truth Behind Moderna Inc’s Latest Stock Movements
Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...